Onivyde

RSS

irinotecan hydrochloride trihydrate

Authorised
This medicine is authorised for use in the European Union.

Overview

Onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body. Onivyde is used together with 5-fluorouracil and leucovorin (two other cancer medicines) in adults whose cancer has got worse despite treatment containing the cancer medicine gemcitabine.

Pancreatic cancer is rare, and Onivyde was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 December 2011.

This EPAR was last updated on 13/06/2019

Authorisation details

Product details
Name
Onivyde
Agency product number
EMEA/H/C/004125
Active substance
irinotecan hydrochloride trihydrate
International non-proprietary name (INN) or common name
irinotecan hydrochloride trihydrate
Therapeutic area (MeSH)
Pancreatic Neoplasms
Anatomical therapeutic chemical (ATC) code
L01XX19
OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Les Laboratoires Servier
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
14/10/2016
Contact address
Les laboratoires Servier
50, rue Carnot
F-92284 Suresnes Cedex
France

Product information

29/03/2019 Onivyde - EMEA/H/C/004125 - IAIN/0014

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 fluorouracil (5 FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy.

Assessment history

How useful was this page?

Add your rating
Average
1 rating